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A b s t r a c t
Introduction: Vertebrobasilar territory ischemia leads to disabling neurological symptoms and may be caused both by vertebral 
artery (VA) and subclavian artery (SA) stenosis. The coexisting symptomatic ipsilateral VA and proximal SA stenosis should be con-
sidered as a true bifurcation lesion for percutaneous treatment.
Aim: To evaluate the safety and efficacy of simultaneous angioplasty of vertebral and subclavian stenosis.
Material and methods: Fifteen patients (age 69.5 years, 46.7% men, all symptomatic from posterior circulation (history of 
stroke, transient ischemic attack, chronic ischemia symptoms)) were scheduled for simultaneous SA/VA angioplasty. Clinical and 
duplex ultrasound follow-up was conducted 1, 6 and 12 months after the procedure.
Results: The technical success rate was 100%. Single balloon-mounted stent angioplasty was performed for all VAs and for 13 
(86.7%) SAs. In 4 cases a simultaneous radial and femoral approach was required. The mean North American Symptomatic Carot-
id Endarterectomy Trial (NASCET) VA stenosis was reduced from 88.7 ±9.7% to 5.7 ±6.8% and SA stenosis from 80 ±12.2% to 11 
±12.3% (p < 0.01). No periprocedural death, stroke, myocardial infarction or transient ischemic attack occurred. During follow-up 
(range: 6–107 months) in 10 of 15 (66.7%) patients relief of chronic ischemic symptoms was observed. No stroke/TIA occurred. 
One cardiovascular and 2 non-cardiovascular deaths were recorded. There was 1 symptomatic vertebral and 1 subclavian in-stent 
restenosis, and 2 cases of asymptomatic VA in-stent occlusion occurred.
Conclusions: Simultaneous vertebral and subclavian artery stenting is safe and effective. The restenosis rate remains at an ac-
ceptable level and it may be treated successfully with drug-eluting balloon angioplasty. In selected patients a dual radial and femoral 
approach may facilitate the procedure.
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Introduction
The prevalence of subclavian artery (SA) stenosis in 
the general population is about 2% [1]. The real prev-
alence of extracranial vertebral artery (VA) stenosis 
generally is unknown, with estimates ranging from 7% 
to 40%. Approximately one-quarter of ischemic strokes 
involve the vertebrobasilar circulation, and stenosis of 
the proximal VA may account for up to 20% of these 
events [2, 3].
In 98% of cases, VA arises from the proximal segment 
of the SA; however, coexisting stenosis of these arteries 
is uncommon. The majority of subclavian artery stenoses 
occur proximally to the origin of the VA, leading to VA 
flow reversal. Most patients remain asymptomatic due to 
contralateral VA supply increase. This phenomenon also 
plays a role in VA stenosis. Incidental SA stenosis in the 
absence of symptoms rarely requires revascularization 
treatment even if 3rd degree VA flow reversal is present. 
However, in cases of inadequate collateral circulation 
supply or combination of vertebral and subclavian steno-
sis, typically symptoms occur mainly due to vertebrobas-
ilar insufficiency [4, 5].
Surgical and endovascular approaches are available 
options of SA/VA stenosis treatment. However, it has 
been shown that endovascular intervention is much saf-
er for this territory, and with advances in device tech-
nology, stent supported angioplasty has become the first 
line treatment [5, 6].
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Aim
The primary objective of this study is to evaluate the 
safety and efficacy of simultaneous subclavian and verte-
bral artery stenting.
Material and methods
Between February 2007 and July 2015 fifteen cases of 
patients with severe, symptomatic subclavian and verte-
bral artery stenosis were retrospectively extracted from 
the SA/VA angioplasty database in a single, high-volume 
center. The diagnosis of SA/VA stenosis was confirmed 
by Doppler ultrasound (DUS) and/or computed tomog-
raphy angiography. Clinical symptoms, despite optimal 
medical therapy, were vertebrobasilar insufficiency (in-
cluding vertigo, recurrent syncope) in all cases, prior pos-
terior cerebrovascular incident in 5 (33.3%) cases, upper 
extremity exertional ischemia in 9 (60%) cases and sub-
clavian-coronary steal syndrome in 1 (6.7%) patient after 
coronary artery bypass grafting. In the group with prior 
stroke/TIA 4 patients presented vertigo and 1 recurrent 
syncope. 
Table I shows detailed patient characteristics.
The qualification for simultaneous vertebral and sub-
clavian artery angioplasty was performed on the basis 
of non-invasive examinations, neurological, cardiolog-
ical and radiological consultation, and finally on direct 
angiography. Non-invasive diagnostics also includes ECG 
Holter monitoring to exclude significant arrhythmias, 
and transthoracic/transesophageal echocardiography to 
exclude cardiac origin embolization. 
All patients received pretreatment with aspirin (75 mg/ 
day) and a 300 mg loading dose of clopidogrel before the 
procedure. After the angioplasty acetylsalicylic acid was 
maintained indefinitely, and 75  mg/day of clopidogrel 
was continued for the following 3 months for bare metal 
stents and 12 months for drug-eluting stents.
The percutaneous arterial approach was obtained via 
the femoral artery in 11 (73.3%) patients. A  combined 
femoral and radial approach was required in 4 patients. 
The etiology of the obstructive lesions was atherosclero-
sis in all cases.
On the procedure day, the femoral artery was punctured 
and an 8 Fr short arterial sheath was introduced. In cases 
with combined access a 6 Fr sheath in the ipsilateral radial 
artery was used. Before angioplasty a weight-adjusted dose 
of unfractionated heparin was administered. Over a 0.035 
inch diagnostic wire, an 8 Fr guiding catheter was advanced 
toward the stenosis. Subclavian lesions were crossed using 
a 0.018 inch wire or steerable 0.035 inch hydrophilic coated 
wire. At the distal segment of the vertebral artery a 0.014 
inch coronary guidewire was positioned. In a case of total 
occlusion, a lesion was successfully crossed from radial ac-
cess with a 0.035 inch hydrophilic-coated guidewire. 
The VA neuroprotection was not used as the system 
retrieval might be problematic in case of the VA ostium 
being covered by the SA stent. Direct stenting was per-
formed when possible. Before and after the procedure 
the degree of stenosis was evaluated by quantitative an-
giography (Figures 1 A–D, 2 A–E).
The study participants were evaluated at 1, 6 and 
12 months and then at yearly intervals after the proce-
dure. Clinical/neurological examination, blood pressure 
measurement in both arms and ultrasonography were 
performed. In patients with significant restenosis con-
firmed by computed tomography (CT) angiography, re-an-
gioplasty with drug-eluting ballon (DEB) was performed. 
Results
Coexisting subclavian and vertebral artery stenosis 
was diagnoses in 15 out of 401 patients with SA stenosis 
and out of 459 patients with VA stenosis; all cases were 
left-side. Of those, one left subclavian occlusion with left 
vertebral stenosis was successfully treated by stenting 
(Figures 3 A–E). In all cases, subclavian artery stenting 
Table I. Baseline clinical characteristics of pa-
tients (N = 15)
Parameter Result
Age [years] 69.5 ±9.3
Sex, male 7 (46.7%)
Vertigo 14 (93.3%)
Recurrent syncope 2 (13.3%)
Prior stroke/TIA 5 (33.3%)
TIA 1 (6.7%)
Pontine stroke 1 (6.7%)
Left sided cerebellar stroke 2 (13.3%)
Occipital lobe stroke 1 (6.7%) 
Coronary subclavian steal 1 (6.7%)
Arm claudication 9 (60%)
Steal syndrome 6 (40%)
Hypertension 15 (100%)
Diabetes mellitus 2 (13.3%)
Dyslipidemia 15 (100%)
Coronary artery disease 8 (53.3%)
Previous percutaneous coronary intervention 5 (33.3%)
Previous myocardial infarction 3 (20%)
History of coronary artery bypass grafting 3 (20%)
Contralateral vertebral artery occlusion 1 (6.7%)
Coexisting carotid artery stenosis 6 (40%)
TIA – transient ischemic attack.
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Figure 1. A – Selective angiography confirming left subclavian stenosis. B – Subclavian steal syndrome – flow 
reversal in the left vertebral artery (large arrow). C – Vertebral artery stenosis after subclavian stenting (small 
arrow). D – Final angiography showing optimal effect on VAS and SAS. E – Bare metal stent restenosis in the 
vertebral artery. F – Final effect after Dior 3.0 × 15 mm drug-eluting balloon dilatation
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Figure 2. A – Left vertebral and subclavian artery 
critical stenosis. B – Simultaneous predilatation.  
C – Balloon-expandable Omnilink 7.0 mm × 28 mm 
SA stenting. D – Balloon-expandable Xience (DES) 
3.0 mm × 8 mm VA direct stenting. E – Final angi-
ography showing optimal effect
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Figure 3. A – Selective angiography from combined approach. B – Unsuccessful attempt at crossing through 
occluded subclavian artery from femoral approach. C – Successful crossing via radial approach. D – After bal-
loon-expandable Omnilink 9.0 mm × 39 mm stent implantation. E – Balloon-expandable Omega (BMS) 4.0 mm 
× 12 mm VA direct stenting. F – Final angiography
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was the first procedure, and VA stent-supported angio-
plasty was performed after rewiring. In 2 of these 15 pa-
tients VA stenting was necessary due to severe plaque 
shift after subclavian artery stenting (SAS). Final kissing 
was performed with a non-compliant balloon in VA when 
needed. Technical success defined as stent implantation 
with residual stenosis < 20%, no significant dissection and 
normal flow was achieved in all 15 (100%) cases of ver-
tebral and in 13 (86.7%) cases of subclavian artery stent-
ing. In 2 cases of SA self-expandable stent-supported an-
gioplasty, the nominal stent diameter was not achieved 
due to increasing local pain during post-dilatation and 
the risk of artery perforation; thus 30% and 40% residual 
stenosis were measured. In all cases of VA angioplasty 
and in 12 cases of SA angioplasty single balloon-mounted 
stents were used. The mean North American Symptom-
atic Carotid Endarterectomy Trial (NASCET) VA stenosis 
was reduced from 88.7 ±9.7% to 5.7 ±6.8% and SA steno-
sis from 80 ±12.2% to 11 ±12.3% (p < 0.01). The prepro-
cedural discrepancy in systolic blood pressure between 
the upper extremities ranged from 15 to 57 mm Hg with 
a  mean of 32.5 mm Hg. The postprocedural differences 
ranged from 0 to 20 mm Hg with a mean of 5.5 mm Hg 
(p < 0.01). Procedural data are summarized in Table II. 
No periprocedural death, stroke, myocardial infarc-
tion or transient ischemic attack occurred. In 11 patients 
with symptomatic coronary artery disease, coronary an-
giography was performed. Three of these patients un-
derwent successful percutaneous coronary angioplasty 
2–6 weeks after VA/SA stenting. During follow-up (range: 
6–107 months) in 10 of 15 patients release of chronic 
ischemia symptoms was observed. No new posterior 
circulation stroke/transient ischemic attack (TIA) oc-
curred. In 2 out of 3 patients with recurrent symptoms, 
critical restenosis was revealed – one in a  VA stent 
(at 31 months of follow-up; Figure 1 E) and the second in 
an SA stent (13 months after the initial procedure). Both 
were successfully redilated with a drug-eluting balloon – 
Freeway 7.0 × 20 mm (Eurocor) and Dior 3.0 × 15 mm (Eu-
rocor) (Figure 1 F). In 1 patient, borderline (50%) left VA 
in-stent restenosis occurred 11 months after angioplasty 
and the patient was qualified for pharmacological treat-
ment. In duplex ultrasound follow-up asymptomatic in-
stent occlusion of the VA was revealed in 2 cases, the first 
after 5 months, the second 8 months after the procedure. 
During the follow-up 3 deaths were recorded, the first due 
to acute kidney failure (26 months follow-up), the second 
due to myocardial infarction (30 months follow-up) and 
the third due to liver cancer (49 months follow-up). 
Periprocedural and follow-up Duplex ultrasound data 
are summarized in Table III. 
Discussion
The majority of subclavian artery stenoses occur prox-
imally to the ostium of the vertebral artery. The left sub-
clavian artery is involved more often than the right. The 
proposed potential mechanism is that the acute angle of 
the origin of the left SA increases flow turbulence and ac-
celerates atherosclerosis at the subclavian-aortic junction 
[7, 8]. Despite VA flow reversal, only the minority of the 
patients become symptomatic. However, the risk of stroke 
and TIA recurrence in symptomatic patients may be three 
times higher compared with patients without stenosis [9]. 
The endovascular procedure, which is less invasive and 
shorter as compared to surgery, may be more beneficial, 
especially in patients with serious comorbidities [6, 10].
In our study all lesions were treated with stents as 
primary stenting has been shown to improve long-term 
Table II. Procedural data
Procedure Result
Left vertebral 15 (100%)
Left subclavian 15 (100%)
Vertebral:
Balloon-expandable bare-metal stent 9 (60%)
Balloon-expandable drug-eluting stent 6 (40%)
Stent diameter [mm] 2.5–5.0
Stent length [mm] 8–14
Direct stenting 11 (73.3%)
Angiographic stenosis evaluation:
Pre-intervention 88.7 ±9.7%
Post-intervention 5.7 ±6.8%
Subclavian:
Occlusion 1 (6.7%)
Balloon-expandable stent 12 (80%)
Self-expandable stent 3 (20%)
Stent diameter [mm] 6–9
Stent length [mm] 17–39
Direct stenting 10 (63.7%)
Angiographic stenosis evaluation:
Pre-intervention 80 ±12.2%
Post-intervention 11 ±12.3%
Inter-arm systolic blood pressure difference [mm Hg]:
Pre-intervention, mean ± SD 32.5 ±13.5
Post-intervention, mean ± SD 5.5 ±6.1
Access:
Femoral 11 (73.3%)
Combined 4 (26.7%)
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patency compared with balloon procedures alone [11, 
12]. Despite higher rates of restenosis as compared to 
other treatment options, balloon angioplasty may be 
considered in patients who are unable to tolerate open 
surgery and/or with contraindications to dual-antiplate-
let therapy. 
In subclavian artery angioplasty, we preferred bal-
loon-expandable stents, especially for ostial lesions. They 
offer higher radial force and more precise deployment, 
which allows one to avoid incidental coverage the origin 
of the vertebral or internal mammary artery. On the other 
hand, self-expanding stents are easier to deliver through 
a tortuous lesion. 
It is well known that small caliber arteries are more 
prone to restenosis as compared to larger arteries. The 
use of drug-eluting stents (DES) in these arteries might 
be of benefit [13–15]. In our study 6 DES were used in 
the vertebral lesions with 1 in-stent occlusion. There was 
1 case of restenosis and 1 case of occlusion in bare-metal 
stents (Table III). 
Simultaneous vertebral and subclavian artery stent-
ing is a  technically demanding endovascular procedure 
which should be performed in high-volume centers. In 
some cases wiring of the vertebral artery may be chal-
lenging due to tortuosity of the vessel and multiple views 
may be required to adequately visualize the VA ostium. 
For this reason a radial approach may be beneficial espe-
cially when proximal SA stenosis displaces the wire away 
from the artery ostium (Figure 2 A) [16]. 
Vertebrobasilar ischemia may be provoked both by 
vertebral and subclavian artery stenosis. Therefore simul-
taneous artery stenting seems to be the optimal solution. 
There is also no need for subsequent hospitalization for 
a second procedure, which decreases the risk of possi-
Table III. Periprocedural and follow-up Duplex ultrasound data
No. SA stent VA stent SA PSV 
before 
procedure 
[m/s]
Ostium VA PSV/
EDV before  
procedure [m/s]
SA PSV after 
procedure 
[m/s]
VA V2 PSV/
EDV after  
procedure 
[m/s]
Follow-up  
(5–65 months) 
SA PSV  
[m/s]
Follow-up  
(5–65 months)
VA V2 PSV/EDV 
[m/s]
1 Omnilink1 
6.0/18 mm
BMS Volo6  
3.0/11 mm
6.5 4.2/1.1 2.2 1.24/0.4 3.0 0.4/0.2
2 Acculink1 
7.0/30 mm
BMS Zeta1  
3.0/13 mm
5.5 Flow reversal, 
plaque shift
1.2 0.46/0.12 1.2 0.5/0.2
3 Express2 
7.0/17 mm
BMS Skylor6  
3.0/13 mm
4.0 Occlusion  
suspected
1.86 0.41/0.13 1.4 0.39/0.09
4 Nefro3 
7.0/18 mm
BMS Skylor6  
3.5/10 mm
Unknown Flow reversal 1.46 0.56/0.16 2.2 0.5/0.2 –  
restenosis
5 Omnilink1 
8.0/18 mm
BMS Chopin3  
4.5/8 mm
5.5 Unknown 2.0 1.02/0.23 2.2 0.85/0.19
6 Nefro3 
7.0/16 mm
BMS Liberte2  
4.0/8 mm
5.75 4.5/0.9 1.8 1.3/0.31 1.8 0.15/0.05 – 
borderline 
restenosis
7 Visi-Pro4 
9.0/37 mm
BMS Gazelle7  
4.0/8 mm
5.5 Plaque shift 3.5 1.02/0.21 3.7 1.1/0.3
8 Absolute Pro1 
8.0/30mm
BMS Vision1  
4.0/8 mm
4.0 4.0/1.7 1.8 0.45/0.11 1.4 0.27/0.12
9 Omnilink1 
9.0/39 mm
BMS Omega2  
4.0/12 mm
Occlusion Flow reversal 2.1 0.27/0.11 2.0 Asymptomatic 
occlusion
10 Omnilink1 
9.0/39 mm
DES Nefro3  
5.0/8 mm
4.6 Occlusion  
suspected
2.1 0.38/0.11 2.5 0.4/0.1
11 RX Herculink  
Elite1 
6.5/18 mm
DES Endeavor 
Resolute RX8  
2.5/14 mm
Unknown Flow reversal 2.7 0.61/0.15 2.0 Asymptomatic 
occlusion
12 Zilver5 
8.0/30 mm
DES Endeavor8 
3.5/12 mm
4.5 Flow reversal 2.0 0.56/0.2 4.5 –  
restenosis
0.25/0.08
13 Omnilink1 
7.0/28 mm
DES XienceV1  
3.0/8 mm
8.6 Flow reversal 2.8 0.54/0.12 3.2 0.15/0.05
14 Neptun3  
7.0/20 mm
DES Biomatrix7 
4.0/8 mm
CT angiog-
raphy
CT angiography 2.2 0.7/0.2 2.7 0.76/0.25
15 Omnilink Elite1 
7.0/19 mm
DES Resolute 
Integrity8  
2.75/14 mm
CT angiog-
raphy
CT angiography 1.6 0.45/0.12 2.4 0.3/0.1
*Velocity measurements were made at 60° insonation angle. PSV/EDV – peak systolic velocity/end-diastolic velocity, SA – subclavian artery, VA V2 – V2 segment of 
vertebral artery, BMS – bare metal stent, DES – drug-eluting stent. 1Abbott, 2Boston Scientific, 3Balton, 4ev3, 5Cook Medical, 6Invatec, 7Biosensors, 8Medtronic.
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ble access complications and reduces costs. On the other 
hand, the larger amount of contrast medium used during 
the procedure requires optimal patient hydration and 
kidney function evaluation. 
Conclusions
Simultaneous vertebral and subclavian stenting is 
a  safe and effective procedure with regard to the ini-
tial success rate and long-term patency. Despite severe 
limitations due to retrospective analysis and a  small 
cohort of 15 patients, the restenosis and occlusion rate 
remained at an acceptable level and, if possible, it may 
be treated successfully with drug-eluting balloon angio-
plasty. In selected patients a dual radial and femoral ap-
proach may facilitate the procedure. 
Conflict of interest
The authors declare no conflict of interest.
References
1. Burihan E, Soma F, Iared W. Angioplasty versus stenting for sub-
clavian artery stenosis. The Cochrane database of systematic 
reviews. 2011; 10: CD008461.
2. Bogousslavsky J, Van Melle G, Regli F. The Lausanne Stroke Reg-
istry: analysis of 1,000 consecutive patients with first stroke. 
Stroke 1988; 19: 1083-92.
3. Compter A, van der Worp HB, Algra A, et al. Prevalence and 
prognosis of asymptomatic vertebral artery origin stenosis in 
patients with clinically manifest arterial disease. Stroke 2011; 
42: 2795-800. 
4. Wrotniak L, Kablak-Ziembicka A, Roslawiecka A, et al. Resolu-
tion of ischemic symptoms after percutaneous angioplasty for 
asymptomatic subclavian artery stenosis. J Vasc Surg 2016; 64: 
684-91. 
5. Potter BJ, Pinto DS. Subclavian steal syndrome. Circulation 2014; 
129: 2320-3. 
6. Higashimori A, Morioka N, Shiotani S, et al. Long-term results of 
primary stenting for subclavian artery disease. Catheter Cardio-
vasc Interv 2013; 82: 696-700. 
7. Nicholls SC, Koutlas TC, Strandness DE. Clinical significance of 
retrograde flow in the vertebral artery. Ann Vasc Surg 1991; 5: 
331-6.
8. Labropoulos N, Nandivada P, Bekelis K. Prevalence and impact 
of the subclavian steal syndrome. Ann Surg 2010; 252: 166-70.
9. Gulli G, Marquardt L, Rothwell PM, et al. Stroke risk after pos-
terior circulation stroke/transient ischemic attack and its rela-
tionship to site of vertebrobasilar stenosis: pooled data analysis 
from prospective studies. Stroke 2013; 44: 598-604. 
10. Eberhardt O, Naegele T, Raygrotzki S, et al. Stenting of verte-
brobasilar arteries in symptomatic atherosclerotic disease and 
acute occlusion: case series and review of the literature. J Vasc 
Surg 2006; 43: 1145-54. 
11. Cloud GC, Crawley F, Clifton A, et al. Vertebral artery origin an-
gioplasty and primary stenting: safety and restenosis rates in 
a  prospective series. J Neurol Neurosurg Psychiatry 2003; 74: 
586-90. 
12. Mohammadian R, Sharifipour E, Mansourizadeh R, et al. Angio-
plasty and stenting of symptomatic vertebral artery stenosis. 
Clinical and angiographic follow-up of 206 cases from north-
west Iran. Neuroradiol J 2013; 26: 454-63. 
13. Tank VH, Ghosh R, Gupta V, et al. Drug eluting stents versus bare 
metal stents for the treatment of extracranial vertebral artery 
disease: a meta-analysis. J Neurointerv Surg 2016; 8: 770-4. 
14. Paluszek P, Pieniążek P, Musiałek P, et al. Symptomatic vertebral 
artery stenting with use of bare metal and drug elitings stents. 
Postep Kardiol Inter 2009; 5: 1-6. 
15. Langwieser N, Buyer D, Schuster T, et al. Bare metal vs. drug-elut-
ing stents for extracranial vertebral artery disease: a meta-anal-
ysis of nonrandomized comparative studies. J Endovasc Ther 
2014; 21: 683-92.
16. Maciejewski D, Tekieli Ł, Kabłak-Ziembicka A, et al. Transradi-
al approach for vertebral artery stenting. Postep Kardiol Inter 
2015; 11: 32-6. 
